Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

A novel type of immunoblocking as a means to cure autoimmune diseases

Reference number
Coordinator GU HOLDING AB - Holdingbolaget vid Göteborgs universitet AB
Funding from Vinnova SEK 1 100 000
Project duration April 2009 - April 2012
Status Completed

Purpose and goal

We have developed unique tolerance inducing therapy for treatment of autoimmune disease and allergy, but focused on therapy against rheumatoid arthritis (RA). Current parts of the project involves investigations of the demands that contract research manufacturers may have, conduct animal studies to prepare for clinical studies, develop pharmacokinetic information, compare the treatment to established therapies and taking in experts to develop preclinical, toxicology and clinical programs. And finally to seek business collaboration, soft funding as well as venture capital.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2010-01863

Page statistics